Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins appears in 186 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials186
Recruiting shown22
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
DK222 Study at HopkinsNCT07140315 · lead sponsor · 2027-01-31
RECRUITING
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADTNCT07550517 · lead sponsor · 2026-08-17
RECRUITING
Supraphysiologic Testosterone Priming Induces Darolutamide Extended ResponseNCT07142551 · lead sponsor · 2026-03-09
RECRUITING
Physician- and Patient-based Barriers to NGS TestingNCT07209176 · lead sponsor · 2026-01-06
RECRUITING
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer PatientsNCT06138067 · lead sponsor · 2025-12-01
RECRUITING
Exercise in Prostate CancerNCT06165302 · lead sponsor · 2025-10-16
RECRUITING
The COSMYC Trial (COmbined Suppression of MYC)NCT06922318 · lead sponsor · 2025-08-19
RECRUITING
7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate CancerNCT06826924 · lead sponsor · 2025-06-03
RECRUITING
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)NCT06564623 · lead sponsor · 2025-05-27
RECRUITING
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerNCT06616597 · lead sponsor · 2025-02-13
RECRUITING
SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment OptimizationNCT06389097 · lead sponsor · 2025-02-03
RECRUITING
Study in Patients With Breast Cancer Leptomeningeal MetastasisNCT06638294 · lead sponsor · 2024-11-25
RECRUITING
Gut Microbiome, Adverse Effects, and Markers Through MEtabolic ReprogrammingNCT06536881 · lead sponsor · 2024-08-08
RECRUITING
Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLCNCT05950139 · lead sponsor · 2024-05-13
RECRUITING
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBCNCT06245889 · lead sponsor · 2024-05-01
RECRUITING
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate CancerNCT06059118 · lead sponsor · 2023-10-04
RECRUITING
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CTNCT03861676 · lead sponsor · 2023-08-03
RECRUITING
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLCNCT05254184 · lead sponsor · 2022-11-01
RECRUITING
Cardiometabolic Screening ProgramNCT05386719 · lead sponsor · 2022-06-03
RECRUITING
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT04704505 · lead sponsor · 2022-04-28
RECRUITING
Sequential Testosterone and Enzalutamide Prevents Unfavorable ProgressionNCT04363164 · lead sponsor · 2020-08-19
RECRUITING
Immunobiology Blood and Tissue Collection of Upper Aerodigestive MalignanciesNCT05995821 · lead sponsor · 2016-08-25
RECRUITING
Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNCT07793253 · lead sponsor · 2026-11-01
NOT_YET_RECRUITING
Biopsy Collection for Men Undergoing Brachytherapy for Prostate CancerNCT04243473 · lead sponsor · 2026-01-01
WITHDRAWN
Behavioral Weight Loss for Cancer Survivors in Maryland: A Trial With Adaptive InterventionsNCT06463249 · lead sponsor · 2024-06-17
ACTIVE_NOT_RECRUITING
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate CancerNCT06014255 · lead sponsor · 2024-02-16
ACTIVE_NOT_RECRUITING
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate CancerNCT05574712 · lead sponsor · 2024-01-01
WITHDRAWN
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate CancerNCT05501548 · lead sponsor · 2023-06-30
TERMINATED
Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without NivolumabNCT05472623 · lead sponsor · 2023-03-21
WITHDRAWN
SMART-ER: Symptom Monitoring With Patient-reported OutcomesNCT05560685 · lead sponsor · 2022-10-03
TERMINATED
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate CancerNCT05081193 · lead sponsor · 2022-03-07
ACTIVE_NOT_RECRUITING
Adaptive Nutrition and Exercise Weight Loss (A-NEW) StudyNCT04499950 · lead sponsor · 2021-02-08
COMPLETED
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate CancerNCT04528199 · lead sponsor · 2021-02-01
TERMINATED
PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)NCT04524195 · lead sponsor · 2021-02-01
TERMINATED
Improving Cancer On-treatment Symptom ManagementNCT04589247 · lead sponsor · 2020-11-16
COMPLETED
Bariatric Arterial Embolization for Men Starting Hormones for Prostate CancerNCT04331717 · lead sponsor · 2020-11-16
WITHDRAWN
Behavioral Weight Loss Program for Cancer Survivors in MarylandNCT04534309 · lead sponsor · 2020-09-22
COMPLETED
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary CancerNCT04116073 · lead sponsor · 2020-04-09
COMPLETED
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer ProgressionNCT04266431 · lead sponsor · 2020-02-20
COMPLETED
Nivolumab in Biochemically Recurrent dMMR Prostate CancerNCT04019964 · lead sponsor · 2020-01-13
COMPLETED
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to TherapyNCT03619655 · lead sponsor · 2019-11-15
TERMINATED
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and TremelimumabNCT03638141 · lead sponsor · 2019-10-02
COMPLETED
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate CancerNCT03800784 · lead sponsor · 2019-10-01
WITHDRAWN
Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate CancerNCT03886493 · lead sponsor · 2019-08-28
TERMINATED
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate CancersNCT04037358 · lead sponsor · 2019-08-09
COMPLETED
Tailored Home-Based Exercise Program for Multiple Chronic ConditionsNCT03874754 · lead sponsor · 2019-08-01
COMPLETED
Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen SuppressionNCT03507608 · lead sponsor · 2019-05-10
COMPLETED
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate CancerNCT03793543 · lead sponsor · 2019-03-27
COMPLETED
Automated Method for Breast Cancer DetectionNCT03863522 · lead sponsor · 2019-03-07
TERMINATED
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate CancerNCT02420977 · lead sponsor · 2018-12-06
COMPLETED
Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerNCT03573648 · lead sponsor · 2018-11-13
ACTIVE_NOT_RECRUITING
Muscadine Plus (MPX) In Men With Prostate CancerNCT03535675 · lead sponsor · 2018-10-30
TERMINATED
Pathologic and Immunologic Response After Ablative Radiation in Lung CancerNCT03603002 · lead sponsor · 2018-10-16
COMPLETED
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene MutationsNCT03413995 · lead sponsor · 2018-09-10
COMPLETED
COMbination of Bipolar Androgen Therapy and NivolumabNCT03554317 · lead sponsor · 2018-09-05
COMPLETED
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBCNCT03439735 · lead sponsor · 2018-07-20
ACTIVE_NOT_RECRUITING
Cancer, Obesity/Overweight and Insomnia StudyNCT03542604 · lead sponsor · 2018-06-12
COMPLETED
Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast CancerNCT03523299 · lead sponsor · 2018-05-22
WITHDRAWN
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate CancerNCT03471650 · lead sponsor · 2018-03-29
ACTIVE_NOT_RECRUITING
Personalized Molecular Profiling in Cancer Treatment at Johns HopkinsNCT02965755 · lead sponsor · 2018-01-26
ACTIVE_NOT_RECRUITING

Sponsor roles

lead sponsor180
collaborator6
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.